Kura Oncology
KURA
30 hedge funds and large institutions have $58.2M invested in Kura Oncology in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
46.22% more ownership
Funds ownership: 0% → 46.22% (+46%)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
7% more funds holding
Funds holding: 28 → 30 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $60.9M → $58.2M (-$2.69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$801K |
| 2 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$158K |
| 3 |
Squarepoint
New York
|
+$67.1K |
| 4 |
OC
Oppenheimer & Co
New York
|
+$58.4K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$45.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$369K |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$157K |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$57.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.99K |
| 5 |
MA
MUFG Americas
New York
|
-$3.06K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
UBS Group
Zurich,
Switzerland
| $10K | -$9.99K | -1,864 | -51% |
|
27
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $5K | – | – | – |
|
|
MA
28
MUFG Americas
New York
| $3K | -$3.06K | -570 | -51% |
|
|
RFA
29
Reilly Financial Advisors
La Mesa,
California
| $1K | – | – | – |
|
|
BC
30
Birchview Capital
Burlington,
Vermont
| – | -$369K | -59,114 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$1K | -200 | Closed |
|
32
Bank of America
Charlotte,
North Carolina
| – | -$327 | -61 | -98% |
|
KURA Hedge Fund Activity: Q4 2016 in Review
30 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2016, worth a combined $58.2M — down 4.4% from $60.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new KURA positions and 2 closed out — a net gain of 2 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $801K. The largest seller was Birchview Capital, exiting entirely with an estimated $369K sold.
- 30 institutional investors held Kura Oncology (KURA) as of Q4 2016, up from 28 in Q3 2016.
- Funds reported $58.2M of Kura Oncology stock for Q4 2016, down 4.4% quarter-over-quarter.
- 4 funds opened new Kura Oncology positions in Q4 2016 and 2 closed out, a net change of +2 holders.
- The largest Kura Oncology buyer in Q4 2016 was Morgan Stanley, an estimated $801K added.
- The largest Kura Oncology seller in Q4 2016 was Birchview Capital, an estimated $369K sold.
Based on aggregated 13F filings for Q4 2016.